CPHI Japan 2023, scheduled for April 19-21, offers a unique opportunity to investigate the far-reaching implications of China’s burgeoning biopharma sector on the Asia-Pacific (APAC) region. Ian Haydock, Editor-In-Chief, Insights, Asia-Pacific at Citeline, will present a keynote address discussing the profound impact of China’s rapidly expanding biopharma industry on the region’s innovation, manufacturing, and outsourcing landscape.
The event, celebrating its 20th anniversary, will host an array of special events, including an award ceremony honoring companies that have played a crucial role in shaping Japan’s thriving pharmaceutical sector. With 7,000 executives from 95 countries expected to attend, CPHI Japan 2023 is set to return to pre-pandemic levels of participation.
China’s increasing focus on Southeast Asia and Japan is reshaping the global biopharma landscape, driving the development of new distribution channels and regional manufacturing hubs. Japan’s innovation environment remains robust, with stable growth, but drug pricing systems persist as a challenge for research-based multinationals operating in the country.
As China’s share of global R&D in new drugs and vaccines rises to 24%, the country’s influence on the APAC region’s biopharma sector cannot be understated. The diverse array of smaller innovators in the APAC biopharma industry is fostering a dynamic supply side with numerous supply partners.